Pharmacyclics Inc., of Sunnyvale, Calif., said it entered a master clinical drug supply agreement with Roche AG, of Basel, Switzerland, to evaluate safety, tolerability and preliminary efficacy of Imbruvica (ibrutinib), an oral Bruton's tyrosine kinase inhibitor, in combination with Gazyva (obinutuzumab), a CD20-directed antibody, in patients with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).